Fengate backs Pilot Fiber's deal for Boldyn Networks' regional fiber network. Fengate Asset Management has agreed to provide more than $330 million in new financing to Pilot Fiber, a New York metropolitan-area enterprise connectivity provider. The investment will support Pilot's acquisition of Boldyn Networks' regional fiber assets and fund the company's continued growth. Pilot's founder and CEO, Joseph Fasone, will continue to lead the company. Pilot provides enterprise fiber connectivity services across the New York metropolitan area. Following the transaction, its owned network is expected to span more than 1,600 route miles of fiber, connecting over 1,200 buildings and 50 data centers. Boldyn's assets will add more than 860 route miles of fiber across New Jersey commercial corridors and expand Pilot's on-net reach into Brooklyn, Queens, the Bronx and Staten Island. Guggenheim Securities served as financial advisor to Fengate, Simpson Thacher & Bartlett provided legal counsel, and Leo Berwick acted as tax and financial due diligence advisor. Goodwin Procter served as legal counsel to Pilot. Sound Point Capital Partners with Ninety One The partnership expands Sound Point's European private credit capabilities into asset-backed lending. To read the entire story, you must be logged in. Talonvest Capital Hires Philippe Castillo Castillo joins Talonvest from Tricon Residential, a portfolio company of Blackstone. To read the entire story, you must be logged in. OpenAI Acquires Orchestra Bio Orchestra Bio provides a platform that helps scientists and drug development leaders collaborate with AI agents in managing complex development programs. To read the entire story, you must be logged in. LSEG Purchases Permira-Backed Octus for $3.54B The deal for Octus will expand its presence in private credit and fixed income data, analytics and workflows. To read the entire story, you must be logged in.

Westcove advises Clinical Research of West Florida in its partnership with Fengate Private Equity. Oct 16, 2026, 09:00 ET LOS ANGELES, Oct. 16, 2026 /PRNewswire/ - Westcove Partners, LLC ("Westcove"), a highly specialized investment bank, announced that it acted as the exclusive financial advisor to Clinical Research of West Florida ("CRWF") in its partnership with Fengate Private Equity, a division of Fengate Asset Management ("Fengate"). The terms of the transaction were not disclosed. Westcove's deal team included Justin Hand, Managing Director; Abe M'Bodj, Managing Director; Bill Bolding, Director; Geno Catalano, Vice President; and Andrew Hartono, Associate. Clinical Research of West Florida is a leading independent clinical research platform operating three Phase I-IV facilities across the Tampa Bay area. Founded in 1995, CRWF has conducted 1,000+ trials across a broad range of therapeutic areas, with differentiated expertise in complex autoimmune and rheumatology indications. The Company's experienced investigator base, proprietary patient database, and preferred relationships with leading sponsors and CROs have established CRWF as a trusted partner for high-quality trial execution and patient enrollment. Aydin Keskiner, Owner and President of Clinical Research of West Florida, commented, "Westcove was unquestionably the right partner for us. Their understanding of our business and the clinical research industry as a whole, was evident throughout the process. From the outset, we felt they always had our back and were fully invested in achieving the best outcome for our company and team. Most importantly, they recognized the value of the organization we had built and what mattered most to us in a partner. We are very excited to partner with Fengate and continue building CRWF into a leading clinical research platform." Bill Bolding, Director of Westcove, commented, "CRWF has all the core attributes of a quality clinical research platform. Aydin and the team have a clear vision for expanding that model across new markets and therapeutic areas, and Fengate brings the resources and experience to help accelerate that growth. We are excited to see CRWF enter its next chapter with a partner so closely aligned with its strategic objectives." About Clinical Research of West Florida Clinical Research of West Florida is an independent clinical research organization serving the Tampa Bay area for more than 30 years. The Company conducts Phase I-IV clinical trials across a diverse range of therapeutic areas, with particular expertise in complex autoimmune and rheumatology indications. CRWF works with leading pharmaceutical sponsors and CROs to advance the development of new therapies through high-quality clinical execution and patient-centered care. For more information, visit www.crwf.com. About Fengate Private Equity Fengate Asset Management is a leading alternative investment manager, with more than $20 billion in assets under management, focused on private equity, infrastructure and real estate strategies. With offices and team members across Canada and the United States, Fengate leverages more than 50 years of entrepreneurial experience to deliver excellent investment results on behalf of its clients. Fengate Private Equity, a division of Fengate Asset Management, is a differentiated investment platform supporting the growth ambitions of entrepreneurs through transformative capital. For more information, visit www.fengate.com. About Westcove Partners Westcove Partners is a premier healthcare-focused investment bank specializing in mergers and acquisitions, debt and equity financings, and other complex corporate finance transactions. The firm is dedicated to advising founder-operated businesses, tailoring its advisory services to address the unique challenges and opportunities these businesses face. For more information, visit www.westcove.com. SOURCE Westcove Partners, LLC

Fengate Private Equity acquires majority stake in Clinical Research of West Florida. GlobeNewswire Published Oct 13, 2026 Investment extends Fengate's pharma services strategy from commercialization into clinical development TAMPA & CLEARWATER, FL, Oct. 13, 2026 (GLOBE NEWSWIRE) - Fengate Private Equity, a division of Fengate Asset Management ("Fengate"), is pleased to announce it has acquired a majority stake in Clinical Research of West Florida ("CRWF" or "the Company"), an independent clinical research site network serving the Tampa Bay region. The investment marks the healthcare team's second pharma services platform investment, extending Fengate's coverage from commercialization into clinical development. Fengate is managing this investment on behalf of the LiUNA Pension Fund of Central and Eastern Canada (LPFCEC). Story continues below This advertisement has not loaded yet, but your article continues below. Founded in 1995 by Lynne Merriam and led since 2002 by President Aydin Keskiner, CRWF operates three state-of-the-art research facilities across Tampa and Clearwater, including a dedicated Phase I unit. Six board-certified principal investigators lead the company's clinical team with deep expertise in autoimmune, pulmonology and endocrinology, among other therapeutic areas. CRWF has supported more than 1,000 trials across Phase I through IV for nearly 300 global biopharmaceutical sponsors and contract research organizations (CROs). Top Stories Interested in more newsletters? Browse here. With Fengate's support, CRWF will expand its trial capacity through continued investment in talent, site infrastructure, and therapeutic depth. The Company will seek to partner with independent sites that have strong investigators and established patient communities, alongside new site development. "Sponsors and CROs increasingly need site partners that can deliver consistent enrollment, quality and execution at scale," said Maxim Tcherner, Managing Director at Fengate Private Equity. "CRWF has built an exceptional 30-year track record defined by strong patient care, clinical excellence and trusted sponsor relationships. Clinical research is a priority within our healthcare strategy, and we believe CRWF is the right platform to build a leading regional network while preserving the qualities that have made the company successful." Story continues below This advertisement has not loaded yet, but your article continues below. "Advancing science and improving lives has been our mission since inception. We have built CRWF as a family business, site by site, with investigators and a clinical team that has been with us for decades," said Aydin Keskiner, President at CRWF. "Fengate brings the capital, industry expertise, and sponsor relationships to expand beyond Southwestern Florida. We'll grow CRWF opening new sites in high-demand markets and partnering with independent site owners who want the resources to grow. What we won't change is the experience patients have here." Westcove Partners served as financial advisors to CRWF. Financial terms of the transaction were not disclosed. About Clinical Research of West Florida Clinical Research of West Florida (CRWF) is an independent clinical research site network serving the Tampa Bay area. Founded in 1995, CRWF operates three research facilities across Tampa and Clearwater, including a dedicated Phase I unit. Its team of board-certified principal investigators has supported more than 1,000 clinical trials across Phase I through IV, with experience in autoimmune, pulmonology, endocrinology, among others. CRWF partners with biopharmaceutical sponsors and contract research organizations and draws on a database of more than 35,000 patients. Learn more at www.crwf.com. This advertisement has not loaded yet. About Fengate Asset Management Fengate Asset Management is a leading alternative investment manager, with more than $19+ billion in assets under management, focused on private equity, infrastructure and real estate strategies. With offices and team members across Canada and the United States, Fengate leverages more than 50 years of entrepreneurial experience to deliver excellent investment results on behalf of its clients. Fengate Private Equity, a division of Fengate Asset Management, is a differentiated investment platform supporting the growth ambitions of entrepreneurs through transformative capital. Learn more at www.fengate.com. Vanessa Naughton Fengate Asset Management +1 416-709-3962 [email protected] This advertisement has not loaded yet.